Large Studies Needed To Further Confirm Prostate Cancer Drug Abiraterone

�Larger trials are needful to further examine and confirm the early findings on the experimental drug abiraterone acetate rayon (CB7630). Researcher Dr. Johann de Bono, from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in the UK, who light-emitting diode two on-going clinical trials of CB7630, said bigger studies are necessary to find out the efficaciousness of the drug.
"We believe we have made a major step frontwards in the treatment of end-stage prostate cancer patients," De Bono told BBC News. He, however, added that the phase 1 and 2 findings requisite to be confirmed in larger trials.



An unwritten and irreversible inhibitor of the enzyme CYP17 that decreases testosterone and DHT to